Save time and get answers to complex questions with AI chat
Abbvie humira patent cliff navigation success?When genetic tenofovir alafenamide be available in us?Drugpatentwatch trametinib?Somatuline depot patent expiry date?When will generic fiasap insulin be available?
See the DrugPatentWatch profile for Xolair
Xolair (omalizumab) is supplied as a solution for subcutaneous injection. The usual formulation strength is: - 150 mg/mL (concentration) Common per-injection doses (based on this concentration) are: - 75 mg = 0.5 mL - 150 mg = 1 mL - 300 mg = 2 mL - Up to 600 mg per injection (which would be 4 mL) Note: - Dosing is given every 2 or 4 weeks and is based on body weight and baseline IgE level. - Some markets offer higher-concentration formulations to reduce injection volume; check your local product specifications. If you want, tell me your country or the exact packaging you’re looking at, and I can confirm the available strengths for that market.
Other Questions About Xolair :